mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice
BACKGROUND: Cerebral cavernous malformations (CCMs) are vascular malformations that frequently cause stroke. CCMs arise due to loss of function in one of the genes that encode the CCM complex, a negative regulator of MEKK3-KLF2/4 signaling in vascular endothelial cells. Gain-of-function mutations in PIK3CA (encoding the enzymatic subunit of the PI3K (phosphoinositide 3-kinase) pathway associated with cell growth) synergize with CCM gene loss-of-function to generate rapidly growing lesions.
METHODS: We recently developed a model of CCM formation that closely reproduces key events in human CCM formation through inducible CCM loss-of-function and PIK3CA gain-of-function in mature mice. In the present study, we use this model to test the ability of rapamycin, a clinically approved inhibitor of the PI3K effector mTORC1, to treat rapidly growing CCMs.
RESULTS: We show that both intraperitoneal and oral administration of rapamycin arrests CCM growth, reduces perilesional iron deposition, and improves vascular perfusion within CCMs.
CONCLUSIONS: Our findings further establish this adult CCM model as a valuable preclinical model and support clinical testing of rapamycin to treat rapidly growing human CCMs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Stroke - 54(2023), 11 vom: 01. Nov., Seite 2906-2917 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Lun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Class I Phosphatidylinositol 3-Kinases |
|---|
| Anmerkungen: |
Date Completed 27.10.2023 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/STROKEAHA.123.044108 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362431779 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362431779 | ||
| 003 | DE-627 | ||
| 005 | 20240210232649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/STROKEAHA.123.044108 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM362431779 | ||
| 035 | |a (NLM)37746705 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Lun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Cerebral cavernous malformations (CCMs) are vascular malformations that frequently cause stroke. CCMs arise due to loss of function in one of the genes that encode the CCM complex, a negative regulator of MEKK3-KLF2/4 signaling in vascular endothelial cells. Gain-of-function mutations in PIK3CA (encoding the enzymatic subunit of the PI3K (phosphoinositide 3-kinase) pathway associated with cell growth) synergize with CCM gene loss-of-function to generate rapidly growing lesions | ||
| 520 | |a METHODS: We recently developed a model of CCM formation that closely reproduces key events in human CCM formation through inducible CCM loss-of-function and PIK3CA gain-of-function in mature mice. In the present study, we use this model to test the ability of rapamycin, a clinically approved inhibitor of the PI3K effector mTORC1, to treat rapidly growing CCMs | ||
| 520 | |a RESULTS: We show that both intraperitoneal and oral administration of rapamycin arrests CCM growth, reduces perilesional iron deposition, and improves vascular perfusion within CCMs | ||
| 520 | |a CONCLUSIONS: Our findings further establish this adult CCM model as a valuable preclinical model and support clinical testing of rapamycin to treat rapidly growing human CCMs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a humans | |
| 650 | 4 | |a mice | |
| 650 | 4 | |a mutation | |
| 650 | 4 | |a perfusion | |
| 650 | 4 | |a sirolimus | |
| 650 | 4 | |a stroke | |
| 650 | 7 | |a Sirolimus |2 NLM | |
| 650 | 7 | |a W36ZG6FT64 |2 NLM | |
| 650 | 7 | |a Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a Class I Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 700 | 1 | |a Ren, Aileen A |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Siqi |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Yourong S |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jisheng |e verfasserin |4 aut | |
| 700 | 1 | |a Bockman, Jenna |e verfasserin |4 aut | |
| 700 | 1 | |a Mericko-Ishizuka, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Griffin, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Shenkar, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Alcazar, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Lightle, Rhonda |e verfasserin |4 aut | |
| 700 | 1 | |a DeBiasse, Dorothy |e verfasserin |4 aut | |
| 700 | 1 | |a Awad, Issam A |e verfasserin |4 aut | |
| 700 | 1 | |a Marchuk, Douglas A |e verfasserin |4 aut | |
| 700 | 1 | |a Kahn, Mark L |e verfasserin |4 aut | |
| 700 | 1 | |a Burkhardt, Jan-Karl |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stroke |d 1970 |g 54(2023), 11 vom: 01. Nov., Seite 2906-2917 |w (DE-627)NLM000010995 |x 1524-4628 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2023 |g number:11 |g day:01 |g month:11 |g pages:2906-2917 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/STROKEAHA.123.044108 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2023 |e 11 |b 01 |c 11 |h 2906-2917 | ||